Dr. Freedman is an Associate Professor of Medicine at Harvard Medical School and an Associate Member at the Broad Institute. Broadly speaking, a primary theme in the Freedman lab is to functionally characterize the non-coding genome. These investigations evaluate the epigenetic landscape across the clinical spectrum of prostate tumorigenesis and progression. This work showed that the androgen receptor (AR), the key transcription factor in prostate cancer, is extensively reprogrammed during tumorigenesis. More recently, a novel, somatically acquired enhancer of the AR was identified. This enhancer becomes acetylated in advanced disease and CRISPR-based tools verify the functional relevance of this genomic element. Characterizing the epigenomic landscape across prostate state transitions will lay the foundation for a deeper understanding of the events driving prostate cancer.